STOCK TITAN

Atossa Therapeutics Inc - ATOS STOCK NEWS

Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.

Atossa Therapeutics Inc (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company pioneering novel therapies for breast cancer and breast health conditions. This page provides investors and healthcare stakeholders with comprehensive access to official press releases, clinical trial developments, and regulatory updates directly from the company.

Track progress on key initiatives including (Z)-endoxifen clinical trials, innovative drug delivery systems like intraductal microcatheter technology, and strategic partnerships. Our curated news collection ensures timely updates on FDA communications, research milestones, and intellectual property developments relevant to oncology therapeutics.

Discover updates across three primary categories: clinical research advancements in estrogen receptor-targeted treatments, regulatory filings for breast cancer therapies, and scientific collaborations enhancing drug delivery platforms. Each update is sourced from verified company communications to maintain accuracy and compliance.

Bookmark this page for streamlined access to Atossa's latest developments in selective estrogen receptor modulation and precision medicine. Regularly updated to serve as your primary resource for understanding the company's progress in addressing unmet needs in oncology care.

Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) appoints Dr. Arezoo Mirad as Senior Medical Director, aiming to accelerate the (Z)-endoxifen development program. With four ongoing Phase 2 trials and important data expected in 2024, the company anticipates improving the standard of care for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
management
-
Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) has reached full enrollment in the Karisma-Endoxifen clinical trial, a Phase 2 study investigating (Z)-endoxifen in premenopausal women with measurable mammographic breast density (MBD). The trial aims to measure reduction in MBD as a proxy for therapy response. The study is expected to provide data in the second half of 2024, with potential implications for breast cancer prevention and novel treatments like (Z)-endoxifen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
-
Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) achieved significant enrollment milestones in ongoing Phase 2 clinical trials for (Z)-endoxifen, including a study in DCIS. The company ended Q3 2023 with $94.0 million in cash and cash equivalents. Key developments include 80% enrollment in ongoing trials, initiation of a new Phase 2 study, approval from Health Canada for a clinical trial, and a research agreement with Weill Cornell Medicine. Financial results show a decrease in operating expenses for Q3 2023 compared to Q3 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced the appointment of Jonathan Finn, CFA, to its board of directors. Finn brings over 25 years of financial industry experience, specializing in early to mid-stage biotech and technology companies. His appointment is expected to accelerate growth and commercialize assets, with critical data readouts expected next year. With four ongoing Phase 2 trials and a strong multi-year cash position, Atossa is well positioned to deliver on its vision of fundamentally changing the breast cancer treatment paradigm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.04%
Tags
management
-
Rhea-AI Summary
Quantum Leap Healthcare Collaborative (QLHC) has launched a Phase 2 platform study called RECAST DCIS to prevent the progression of DCIS to breast cancer. The study is evaluating three investigational endocrine therapy arms: (Z)-endoxifen, HAVAH T+Ai™, and ORSERDU®. The trial aims to reduce unnecessary surgeries and overtreatment of DCIS patients by offering up to six months of endocrine therapy and long-term active surveillance. Each investigational agent arm is expected to enroll up to 110 patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
-
Rhea-AI Summary
Cognito Therapeutics appoints Greg Weaver as CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
management
Rhea-AI Summary
Dr. Steven Quay calls for nutritional guidelines for adolescent girls to reduce future breast cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
-
Rhea-AI Summary
Atossa Therapeutics working on promising drug for breast cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
none
-
Rhea-AI Summary
Atossa Therapeutics to participate in Cantor Fitzgerald Global Healthcare Conference 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.57%
Tags
Atossa Therapeutics Inc

Nasdaq:ATOS

ATOS Rankings

ATOS Stock Data

80.49M
129.09M
0.06%
28.55%
7.05%
Biotechnology
Pharmaceutical Preparations
Link
United States
SEATTLE